Home › Metastatic Cancer › California › San Francisco
Metastatic Cancer clinical trials in San Francisco, CA
28 studies for Metastatic Cancer are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, San Francisco
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RecruitingPhase 1/2
- University of California San Francisco, San Francisco
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- UCSF at China Basin, San Francisco
- UCSF at Mount Zion, San Francisco
- UCSF at Parnassus, San Francisco
- and 1 more
Intratumoral N17350 in Advanced Solid Tumors
RecruitingPhase 1/2
- University of California, San Francisco, San Francisco
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RecruitingPhase 1
- UCSF Medical Center at Mount Zion, San Francisco
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- Kaiser Permanente, San Francisco
- UCSF Medical Center at Mission Bay, San Francisco
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RecruitingPhase 1/2
- UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
RecruitingPhase 1/2
- University of California, San Francisco (UCSF), San Francisco
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- University of California San Francisco, San Francisco
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RecruitingPhase 1/2
- Crinetics Study Site, San Francisco
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
RecruitingPhase 2
- University of California, San Francisco, San Francisco
Imaging of Solid Tumors Using 18F-TRX
RecruitingPhase 1
- University of California, San Francisco, San Francisco
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
RecruitingPhase 1
- University of California San Francisco, San Francisco
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #5, San Francisco
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RecruitingPhase 1
- University of California, San Francisco, San Francisco
Imaging of Solid Tumors Using FAP-2286
RecruitingPhase 1
- University of California, San Francisco, San Francisco
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingPhase 1
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RecruitingPhase 1/2
- University of California San Francisco (UCSF), San Francisco
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RecruitingPhase 2/3
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
Comparison of Whole Body DWI to FDG PET
Recruiting
- University of California, San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
RecruitingPhase 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Venetoclax Basket Trial for High Risk Hematologic Malignancies
RecruitingPhase 1
- University of California San Francisco-Benioff Children's Hospital, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of California, San Francisco, San Francisco
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Lung Cancer22 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Ovarian Cancer19 studies
- Colorectal Cancer18 studies
- Cardiovascular Disease18 studies
- Glioblastoma17 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.